文献速递胸部肿瘤

中央型或>7cm T4 N0/1 M0非小细胞肺癌三联治疗后的早期肿瘤相关死亡与晚期死亡比较

Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve.
PubMed 文献 · Eur J Cancer · 2020-09-02

本研究纳入2000-2015年接受新辅助化疗、同步放化疗(45-46 Gy)后手术的cT4 cN0/1 cM0非小细胞肺癌患者67例,中位随访134个月。2、5、10、15年总生存率分别为83.6%、65.4%、53.3%、36.6%,44.8%达病理完全缓解。治疗前5年年死亡率为8.31%,与8年后年死亡率4.75%相比无显著增加(HR=1.72,95%CI 0.81-3.65)。

要点

  • cT4 cN0/1 cM0非小细胞肺癌三联治疗长期生存良好,5年OS达65.4%
  • ypT分期是最强预测因素,ypT0患者5年OS为80.5%
  • 治疗前5年死亡率与8年后背景死亡率无显著差异

核心结论

  • cT4 cN0/1 cM0非小细胞肺癌接受诱导化疗、同步放化疗后手术的三联方案有效且局部控制率高。
  • 以生存超过8年的年死亡率为背景,该方案将前5年年死亡率降至背景水平,未观察到显著增加的早期死亡。

研究设计与样本

  • 回顾性队列研究,纳入2000-2015年连续收治的经病理确诊的cT4 cN0/1 cM0非小细胞肺癌患者67例。
  • 所有患者接受新辅助化疗、同步放化疗(45-46 Gy)及手术切除;T4分期由专家放射科医师按UICC第8版重新分析,纵隔分期采用系统性EBUS-TBNA或纵隔镜检查。
  • 主要终点为总生存期(OS);检验效能>80%以检测治疗前5年与96个月后相比早期肿瘤相关死亡风险比>3.5。

主要发现

  • 中位随访134个月,2、5、10、15年OS率分别为83.6±4.5%、65.4±5.9%、53.3±6.3%、36.6±6.8%。
  • 44.8%的患者达到病理完全缓解;多因素分析中ypT分期是最强预测因素,ypT0(n=31)5年OS为80.5%,ypT1(n=11)为62.5%。
  • 主要失败部位为脑转移(7例)和肺转移(3例)。
  • 治疗前5年年死亡率为8.31%(95%CI 5.60-12.24%),与96个月后年死亡率4.75%(95%CI 2.40-9.27%)相比,风险比1.72(95%CI 0.81-3.65),无显著增加。

临床怎么用

  • 对于中央型或>7cm的T4 N0/1 M0非小细胞肺癌,可考虑诱导化疗联合同步放化疗后手术的三联治疗模式。
  • 治疗后应关注脑和肺转移筛查,ypT分期可辅助预后分层。

局限性

  • 单中心回顾性研究,样本量较小(67例)。
  • 早期死亡与晚期死亡的比较基于生存曲线估算,非直接因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal treatment for patients with locally advanced non-small-cell lung-cancer (NSCLC) cT4 cN0/1 cM0 is still under debate. The purpose of this study was to examine the long-term survival of cT4 cN0/1 cM0 NSCLC patients undergoing induction chemotherapy and concurrent radiochemotherapy before surgery. METHODS: All consecutive patients with confirmed NSCLC (cT4 cN0/1 cM0) treated with neoadjuvant chemotherapy, concurrent radiochemotherapy (RT/CTx) (45-46 Gy) and surgical resection between 2000 and 2015 were included. According to the UICC guidelines (8th edition), T4 stage was reanalysed by an expert radiologist. The mediastinal staging was performed by systematic EBUS-TBNA or mediastinoscopy. The primary end-point was overall-survival (OS). The power to detect an increase of early tumour-associated mortality (hazard ratio > 3.5) within the first 5 years after treatment in comparison to late deaths beyond 96 months was >80%. RESULTS: Overall, 67 patients were treated with concurrent RT/CTx. T4 criteria were fulfilled by all patients, and multiple T4 criteria by 53 patients. Seventy percent of patients had an initial PET/CT staging. The median follow-up period was 134 months. OS rates at 2, 5, 10 and 15 years were 83.6 ± 4.5%, 65.4 ± 5.9%, 53.3 ± 6.3% and 36.6 ± 6.8%, respectively. A total of 44.8% of patients achieved a pathologic complete response. In multivariable analysis, ypT category was the most predictive factor. OS at 5 years for ypT0 (n = 31) was 80.5%, and ypT1 (n = 11) was 62.5%. Main sites of failure were brain and pulmonary metastases in seven and three patients, respectively. The intercurrent annual death rate was estimated from the survival curve beyond 96 months and was found to be 4.75% (95% CI 2.40-9.27%). No significant increased mortality was observed during the first 5 years (annual death rate: 8.31% [95% CI 5.60-12.24%], hazard-ratio = 1.72 [95% CI 0.81-3.65]). CONCLUSIONS: The effectiveness of this trimodality schedule is high in patients with cT4 cN0/1 cM0 NSCLC with excellent local control rates. Considering the annual death rate beyond 8 years of survival as an intercurrent death rate due to comorbidity, this treatment schedule reduces annual mortality to background even in the first 5 years after therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Guberina N, Pöttgen C, Schuler M, et al. Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve. Eur J Cancer. 2020. PMID: 32889370. doi:10.1016/j.ejca.2020.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。